# Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy

> **NCT06840834** · PHASE2 · RECRUITING · sponsor: **Intergroupe Francophone de Cancerologie Thoracique** · enrollment: 38 (estimated)

## Conditions studied

- Pleural Mesotheliomas

## Interventions

- **DRUG:** Ivonescimab

## Key facts

- **NCT ID:** NCT06840834
- **Lead sponsor:** Intergroupe Francophone de Cancerologie Thoracique
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-30
- **Primary completion:** 2026-03-24
- **Final completion:** 2028-03-31
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2026-03-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06840834

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06840834, "Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT06840834. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*